Detalhe da pesquisa
1.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Oncologist
; 28(10): 845-855, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318349
2.
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 382(6): 514-524, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826360
3.
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials.
Oncology
; 99(7): 444-453, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33823518
4.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Cancer
; 125(14): 2400-2408, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951193
5.
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 120(2): 183-189, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30531832
6.
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
Br J Cancer
; 121(5): 429-430, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31350526
7.
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
N Engl J Med
; 375(3): 209-19, 2016 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27264120
8.
Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
Lancet Oncol
; 18(5): 654-662, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28314691
9.
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Future Oncol
; 12(15): 1759-68, 2016 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-27093976
10.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med
; 366(6): 520-9, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149876
11.
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
Br J Haematol
; 165(4): 510-8, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24579926
12.
Everolimus plus exemestane as first-line therapy in HRâº, HER2â» advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
; 143(3): 459-67, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362951
13.
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Lancet Oncol
; 14(3): 249-56, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23414587
14.
A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation.
Cancer Discov
; 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691346
15.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Cancer
; 119(10): 1908-15, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504821
16.
Increased Utilization of Low-Dose CT for Lung Cancer Screening at an Arkansas Community Oncology Clinic.
J Am Coll Radiol
; 2023 Nov 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37984767
17.
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
JAMA Oncol
; 9(1): 40-50, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394849
18.
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Target Oncol
; 18(4): 517-530, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37278879
19.
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Cancer
; 118(5): 1192-201, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21987386
20.
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Clin Breast Cancer
; 22(4): 326-335, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034858